Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    kpt-8602
Previous Study | Return to List | Next Study

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02649790
Recruitment Status : Recruiting
First Posted : January 7, 2016
Last Update Posted : May 3, 2022
Sponsor:
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc

Brief Summary:

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), Acute Myeloid Leukemia (AML) and Newly Diagnosed Intermediate/High-Risk MDS.

Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.


Condition or disease Intervention/treatment Phase
Relapsed/Refractory Multiple Myeloma (RRMM) Metastatic Colorectal Cancer (mCRC) Metastatic Castration Resistant Prostate Cancer (mCRPC) Higher Risk Myelodysplastic Syndrome (HR-MDS) Acute Myeloid Leukemia (AML) Newly Diagnosed Intermediate/High-Risk MDS Drug: KPT-8602 Drug: ASTX727 Drug: Dexamethasone Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 119 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Actual Study Start Date : January 2016
Estimated Primary Completion Date : August 31, 2024
Estimated Study Completion Date : August 31, 2024


Arm Intervention/treatment
Experimental: Part A1: RRMM- KPT-8602 single agent; QoDx5/week
Participants received KPT-8602 once daily for 5 days per week (QDx5/week) at escalated doses (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part A2: RRMM- KPT-8602 single agent; QoDx3/week
Participants received KPT-8602 once daily for 3 days per week (QoDx3/week). The starting dose for Part A2 will be informed by Part A1 (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part B: RRMM- KPT-8602 with low-dose dexamethasone; QDx5/week
Participants received KPT-8602 for 5 consecutive days (QDx5/week) in combination with low dose dexamethasone (20 milligram [mg] on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle) (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Drug: Dexamethasone
Participants will receive dexamethasone oral tablets.

Experimental: Part C: RRCRC- KPT-8602 single agent
Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part D: RRmCRPC- KPT-8602 single agent
Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part E: RRmCRPC- KPT-8602 with abiraterone and corticosteroids
Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A in combination with abiraterone and corticosteroids. Participants continued to receive the dose and schedule of abiraterone and corticosteroids that they were receiving at the time of enrollment (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part F: High-risk Myelodysplastic Syndrome (MDS)- KPT-8602 single agent
Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A. In select cases (for example, participants achieving stable disease [SD], hematological improvement [HI], partial response [PR] and tolerating treatment, etc.), the dose may be escalated 1 level based on safety and efficacy considerations (completed).
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part F Phase 2: High-risk MDS- KPT-8602 single agent
Participants will be enrolled at recommended Phase 2 doses (RP2D) of 10 mg daily on Days 1 to 5 of each week, in a dose expansion, based upon the results from the Phase 1 portion of Part F.
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Experimental: Part G: Newly Diagnosed Intermediate/High-Risk MDS -KPT-8602 with ASTX727
Participants will receive KPT-8602 once daily at escalated doses. The starting dose for KPT-8602 is 5 mg orally once daily from Day 8 to Day 28 (Weeks 2 to 4) on a 28-day cycle in combination with ASTX727.
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.

Drug: ASTX727
ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.

Experimental: Part H: AML Maintenance Therapy- KPT-8602 single agent
Participants with high-risk Acute Myeloid Leukemia (AML) prior to transplant will be enrolled to receive maintenance therapy with KPT-8602 post-allogeneic stem cell transplantation. The dose for KPT-8602 will be 10 mg (RP2D from Part F) oral, to be administered once daily from Day 1 to Day 21 (Weeks 1 to 3) on a 28-day cycle.
Drug: KPT-8602
Participants will receive KPT-8602 oral tablets.




Primary Outcome Measures :
  1. Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ Time Frame: Approximately 4 weeks ]
  2. Part A1, A2, B, C, D, E, F: Overall Response Rate (ORR) [ Time Frame: Approximately 8 years ]
  3. Part A1, A2, B, C, D, E, F: Duration of Response (DOR) [ Time Frame: Approximately 8 years ]
  4. Part A1, A2, B, C, D, E, F: Progression-free survival (PFS) [ Time Frame: Approximately 8 years ]
  5. Part A1, A2, B, C, D, E, F: Overall Survival (OS) [ Time Frame: Approximately 8 years ]
  6. Part A1, A2, B, C, D, E, F: Clinical Benefit Rate (CBR) [ Time Frame: Approximately 8 years ]
  7. Part A1, A2, B, C, D, E, F: Duration of Clinical Benefit Rate (CBR) [ Time Frame: Approximately 8 years ]
  8. Part A1, A2, B, C, D, E, F: Disease control rate (DCR) [ Time Frame: Approximately 8 years ]
  9. Part A1, A2, B, C, D, E, F: Duration of DCR [ Time Frame: Approximately 8 years ]
  10. Part F Phase 2: ORR [ Time Frame: Approximately 8 years ]
  11. Part G: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ Time Frame: Approximately 8 years ]
  12. Part H: 2- Year Progression-free Survival (PFS) [ Time Frame: Approximately Up to 2 years ]

Secondary Outcome Measures :
  1. Part A1, A2, B, C, D, E, F, H: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  2. Part A1, A2, B, C, D, E, F, H: Maximum Observed Plasma Concentration (Cmax) of Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  3. Part A1, A2, B, C, D, E, F, H: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  4. Part A1, A2, B, C, D, E, F, H: Apparent Terminal Half Life (t1/2) of Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  5. Part A1, A2, B, C, D, E, F, H: Apparent Total Body Clearance Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  6. Part A1, A2, B, C, D, E, F, H: Apparent Volume of Distribution During Terminal Phase (VZ/f) of Eltanexor [ Time Frame: Pre-dose 2 hours post-dose Cycle1Day1 and 15; Pre-dose 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Cycle1Day21 and 26; 24 hours post-dose Cycle1Day2, 22,and 27; 48 hours post-dose Cycle1Day23 and 28 and up to approximately 8 years ]
  7. Part F Phase 2: Overall Survival (OS) [ Time Frame: Approximately 8 years ]
  8. Part F Phase 2: 6-Month Overall Survival (OS) [ Time Frame: Approximately Up to 6 Months ]
  9. Part F Phase 2: Progression-free survival (PFS) [ Time Frame: Approximately 8 years ]
  10. Part F Phase 2: Disease control rate (DCR) [ Time Frame: Approximately 8 years ]
  11. Part F Phase 2: Duration of Response (DOR) [ Time Frame: Approximately 8 years ]
  12. Part F Phase 2: Rate of Conversion from Red Blood Cell (RBC) Transfusion Dependence to Independence [ Time Frame: Approximately 8 years ]
  13. Part F Phase 2: Rate of Conversion from Platelet Transfusion Dependence to Independence [ Time Frame: Approximately 8 years ]
  14. Part G: Overall Response Rate (ORR) [ Time Frame: Approximately 8 years ]
  15. Part G: Duration of Response (DOR) [ Time Frame: Approximately 8 years ]
  16. Part H: Rate of Minimal Residual Disease (MRD) Conversion from Positive to Negative [ Time Frame: Approximately 8 years ]
  17. Part H: Time to Minimal Residual Disease (MRD) Negativity [ Time Frame: Approximately 8 years ]
  18. Part H: Percentage of Participants with Acute and Chronic Graft-versus-Host Disease (GVHD) [ Time Frame: Approximately 8 years ]
  19. Part H: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Approximately 8 years ]
  20. Part H: Overall Survival (OS) [ Time Frame: Approximately 8 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  1. Written informed consent signed prior to any screening procedures and in accordance with federal, local, and institutional guidelines.
  2. Age ≥18 years.
  3. Adequate hepatic function:

    1. total bilirubin ≤2 times the upper limit of normal (ULN) (except participants with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤4 times ULN),
    2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN (except participants with known liver involvement of their tumor who must have their AST and ALT ≤5.0 times ULN).
  4. Adequate renal function: estimated creatinine clearance of ≥30 mL/min, calculated using the formula of Cockcroft and Gault (140-Age) × Mass (kg)/(72 × creatinine mg/dL); multiply by 0.85 if female.
  5. Contraception:

    1. Participants with RRMM, CRC, RR high-risk MDS (Part F Phase 2), and AML (Part H): Female participants of child-bearing potential must agree to use dual methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum test at Screening, and male participants must use an effective barrier method of contraception if sexually active. For both male and female participants, effective methods of contraception must be used throughout the study and for 3 months following the last dose.
    2. Participants with RR mCRPC: Participants must use an effective barrier method of contraception if sexually active. Effective methods of contraception must be used throughout the study and for 3 months following the last dose.
    3. Participants with newly diagnosed intermediate/high-risk MDS (Part G): Female participants of child-bearing potential must agree to use dual methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum pregnancy test at Screening, and male participants must use an effective barrier method of contraception if sexually active. For both male and female participants, effective methods of contraception must be used throughout the study and for 6 months following the last dose.

    INDICATION-SPECIFIC INCLUSION CRITERIA

    Relapsed/Refractory Multiple Myeloma (Parts A1, A2, and B - Completed):

  6. Symptomatic, histologically confirmed MM and evidence of disease progression, based on IMWG guidelines.
  7. Participants must have measurable disease as defined by at least 1 of the following:

    1. Serum M-protein ≥0.5 g/dL by serum protein electrophoresis (SPEP) or for immunoglobulin (Ig) A myeloma, by quantitative IgA. If SPEP is felt to be unreliable for routine M-protein measurement (e.g., for participants with IgA MM), then quantitative Ig levels by nephelometry; or
    2. Urinary M-protein excretion at least 200 mg/24 hours; or
    3. Serum free light chain (FLC) whereby the involved light chain measures ≥10 mg/dL and with an abnormal ratio.
  8. Previously treated with ≥3 prior regimens (lines of therapy) that included at least 1 of each of the following: an immunomodulatory drug, a proteasome inhibitor, and a steroid.
  9. MM refractory to the participants most recent anti-MM regimen.
  10. Participants receiving hematopoietic growth factor support including erythropoietin, darbepoetin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, and platelet stimulators can continue to do so, but must be transfusion independent for at least 1 week prior to Cycle 1 Day 1 (C1D1) in the study.
  11. Adequate hematopoietic function: total white blood cell (WBC) count ≥1500/mm^3, absolute neutrophil count (ANC) ≥800/mm^3, hemoglobin (Hb) ≥8.0 g/dL, and platelet count ≥75,000/mm^3.
  12. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
  13. Life expectancy of ≥4 months.

    Relapsed/Refractory Colorectal Cancer (Part C - Completed):

  14. Histological or cytological documentation of adenocarcinoma of the colon or rectum.
  15. Measurable disease by RECIST v1.1.
  16. Metastatic disease not suitable for upfront curative-intent surgery.
  17. Participants with site-defined KRAS status (wild-type or mutant) from a fresh or archival tumor biopsy prior to enrollment. All participants must be willing to have fresh biopsies to obtain tumor tissue for biomarker analysis.
  18. Documented evidence of progressive disease according to RECIST v1.1.
  19. Prior treatment (with completion of a course of therapy, or to disease progression or intolerability) with each of the following:

    1. Fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapies (e.g., FOLFOX and/or FOLFIRI)
    2. if KRAS wild-type, an anti-EGFR therapy,
    3. Prior third line treatment with regorafenib or TAS-102, will be assessed on an individual basis,
    4. Note: The requirement for prior third line regorafenib will be assessed on an individual basis by the investigator in consultation with the Karyopharm Medical Monitor
    5. Radiation and surgery are not considered as prior anticancer regimens
  20. Participants should not be transfusion dependent.
  21. Adequate hematopoietic function: ANC ≥1000/mm^3, hemoglobin (Hb) ≥9.0 g/dL, and platelet count ≥100,000/mm^3.
  22. ECOG performance status of ≤1.
  23. Life expectancy of ≥4 months.

    Relapsed/Refractory Metastatic Castration-resistant Prostate Cancer (Parts D and E - Completed):

  24. Histologically confirmed adenocarcinoma of the prostate with archival tumor tissue available for molecular analyses. If the participants does not have a prior histological diagnosis, then a fresh biopsy at Screening may be used for this purpose.

    a. Optional: All participants will be asked to have fresh biopsies to obtain tumor tissue for biomarker analysis.

  25. Surgically or medically castrated, with testosterone levels of <50 ng/dL (<2.0 nM). If the participant is being treated with luteinizing hormone-releasing hormone (LHRH) agonists (participants who have not undergone orchiectomy), and participants must have shown to progress on this.
  26. Documented mCRPC progression as assessed by the Investigator with 1 of the following:

    1. Prostate-specific antigen (PSA) progression defined by a minimum of 3 rising PSA levels (at approximately Day -30 and approximately Day -45) with an interval of >1 week between each determination. The PSA values at the Screening visit should be >2 μg/L (>2 ng/mL); participants on systemic glucocorticoids for control of symptoms must have documented PSA progression by Prostate Cancer Working Group 3 (PCWG3) while on systemic glucocorticoids prior to commencing C1D1 of treatment.
    2. Radiographic progression of soft tissue disease by modified RECIST criteria 1.1 or of bone metastasis with 2 or more documented new bone lesions on a bone scan with or without PSA progression.
  27. Initial response (per modified PCWG3 Guidelines) to second generation anti-hormonal therapy (examples: abiraterone, enzalutamide, TAK 700), but later relapsed. Disease relapse would be defined as progressive disease at the time of entry per inclusion criterion 24.
  28. Zero to 2 previous taxane-based chemotherapy regimens. If docetaxel chemotherapy is used more than once, this will be considered as 1 regimen. Participants may have had prior exposure to cabazitaxel treatment. Participants may be taxane naïve.
  29. At least 2 weeks from completion of any radiotherapy including a single fraction of radiotherapy for the purposes of palliation (confined to 1 field) is permitted.
  30. Participants should not be transfusion dependent.
  31. Albumin >2.5 g/dL.
  32. Adequate hematopoietic function: ANC ≥1000/mm^3, hemoglobin (Hb) ≥9.0 g/dL, and platelet count ≥100,000/mm^3.
  33. Part E only: Participants currently receiving treatment with abiraterone and appropriate to continue in the opinion of the Investigator. Participants must also have been on and continue on a stable dose of corticosteroids (prednisone or dexamethasone) for 30 days prior to C1D1.
  34. ECOG performance status of ≤1.
  35. Life expectancy of ≥4 months.

    RR High-risk Myelodysplastic Syndrome (Part F Phase 2):

  36. Documented diagnosis of MDS with 5% to 19% myeloblasts in the bone marrow (2016 WHO classification)
  37. The marrow histopathology must be documented by recent bone marrow biopsy
  38. Participants should be intermediate, high- or very-high-risk MDS by IPSS-R
  39. Participants with HMA (primary)-refractory MDS, including:

    1. ≥2 cycles of hypomethylating agents (azacitidine and/or decitabine, ASTX727, or experimental agents) with clear progressive disease (PD) (pancytopenia, with ≥50% increase in bone marrow blasts) or participants progressed to a higher-risk category of MDS OR
    2. ≥4 cycles of azacitidine and/or decitabine (or other hypomethylating therapy) with SD/lack of improvement (no CR/mCR/PR/HI) per IWG criteria
  40. ECOG performance status of <2
  41. Prior to enrolling a participant with imminent risk of AML transformation (per opinion of the Investigator) or for participants with RAEB-2 MDS, the Medical Monitor must be contacted

    Newly Diagnosed Intermediate/High-risk Myelodysplastic Syndrome (Part G):

  42. Documented diagnosis of MDS with 5% to 19% myeloblasts in the bone marrow (2016 WHO classification)

    • The marrow histopathology must be documented in bone marrow biopsy
    • Participants should be intermediate, high- or very high-risk MDS by IPSS-R
  43. No prior therapy for MDS. (One prior cycle of a hypomethylating agent is allowed, but no other cytotoxic chemotherapy is permitted within 2 weeks of starting study treatment.)
  44. ECOG performance status of <2

    AML Maintenance (Post-alloSCT) Therapy (Part H):

  45. Participants with de novo AML or AML secondary to prior myelodysplastic disease
  46. Received an allogeneic SCT
  47. At the time of allogeneic SCT, no prior allogeneic HSCT
  48. Participants must be able to start study treatment between 40 and 100 days following alloSCT
  49. Participants with CR/CRi status confirmed prior to alloSCT according to the following criteria, must also be MRD-positive by multi-parameter flow cytometry (MFC) at either pre-allo or at time of enrollment:

    Complete remission:

    • <5% blasts in bone marrow
    • Absence of blasts with Auer rods
    • Absence of extramedullary disease
    • Independent of blood transfusions
    • Peripheral neutrophil count ≥1.0 x 10^9/L
    • Platelet count ≥100 x 10^9/L

    Complete remission with incomplete blood count recovery:

    • <5% blasts in bone marrow
    • Absence of blasts with Auer rods
    • Absence of extramedullary disease
    • Independent of blood transfusions
    • Peripheral neutrophil count <1.0 x 10^9/L, or
    • Platelet count <100 x 10^9/L
  50. If not in CR/CRi with MRD positivity prior to alloSCT, may have any of the following high-risk features:

    • Relapsed AML, not in CR
    • If CR2 or greater, may enroll regardless of disease characteristics at initial diagnosis
    • High-risk cytogenetics at time of diagnosis
  51. Adequate engraftment within 14 days prior to starting study therapy: ANC ≥1.0 x 10^9/L without daily use of myeloid growth factor, and platelet count 75 x 10^9/L without platelet transfusion within 1 week
  52. ECOG performance status of ≤2

EXCLUSION CRITERIA

Participants in All Parts of the Study:

  1. Female participants who are pregnant or lactating
  2. Major surgery within 4 weeks before C1D1
  3. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    1. Unstable angina or acute myocardial infarction ≤3 months prior to C1D1
    2. Clinically significant heart disease (e.g., symptomatic congestive heart failure [e.g., >NYHA Class 2]; uncontrolled arrhythmia, or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)
  4. Uncontrolled active severe systemic infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1
  5. Participants with known symptomatic brain metastasis are not suitable for enrollment. Participants with asymptomatic, stable, treated brain metastases are eligible for study entry
  6. Participants with a known history of human immunodeficiency virus (HIV); HIV testing is not required as part of this study
  7. Known, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen)
  8. Prior malignancies:

    1. Participants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (i.e., cervix) may enroll irrespective of the time of diagnosis
    2. Participants with relapsed/refractory MM, CRC, and mCRPC only: Prior malignancies which may interfere with the interpretation of the study. Cancer treated with curative intent <5 years previously will not be allowed unless approved by the Sponsor. Cancer treated with curative intent >5 years previously and without evidence of recurrence will be allowed.
    3. For participants in Arms F Phase 2, G, and H: Prior malignancy is not an exclusion
  9. Participants with gastrointestinal tract disease (or uncontrolled vomiting or diarrhea) that could interfere with the absorption of eltanexor (or ASTX727 in Part G)
  10. Serious psychiatric or medical conditions that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give consent
  11. Participants unwilling to comply with the protocol including required biopsies and sample collections required to measure disease

    INDICATION-SPECIFIC EXCLUSION CRITERIA

    Relapsed/Refractory Multiple Myeloma (RRMM) (Parts A1, A2 and B - Completed):

  12. Time since the last prior therapy for treatment of RRMM:

    1. Radiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anticancer therapy ≤2 weeks prior to C1D1
    2. Palliative steroids for disease related symptoms are allowed up to 3 days prior to C1D1.
    3. Participants must have recovered or stabilized (≤Grade 1 or to their baseline) from toxicities related to their previous treatment except for alopecia
  13. Participants with active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation
  14. Grade >2 peripheral neuropathy or Grade 2 peripheral neuropathy with pain within 2 weeks prior to C1D1

    Relapsed/Refractory Colorectal Cancer (Part C - Completed):

  15. Radiotherapy, chemotherapy, or any other anticancer therapy, including investigational anticancer therapy within 2 weeks prior to Screening. Participants must have recovered from clinically significant toxicities. The site of irradiation should have evidence of progressive disease (new lesions or increase in lesion size) if this is the only site of disease
  16. Participants who have been treated with their most recent chemotherapy or investigational drugs ≤21 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment, and/or have any acute toxicities due to prior chemotherapy and/ or radiotherapy that have not resolved to a NCI CTCAE v4.03 Grade 0 or Grade 1 with the exception of chemotherapy induced alopecia and Grade 2 peripheral neuropathy

    Relapsed/Refractory Metastatic Castration-Resistant Prostate Cancer (Parts D and E - Completed):

  17. Participants who have been treated with their most recent chemotherapy or investigational drugs ≤21 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment, and/or have any acute toxicities due to prior chemotherapy and/ or radiotherapy that have not resolved to a NCI CTCAE v4.03 Grade 0 or Grade 1 with the exception of chemotherapy-induced alopecia and Grade 2 peripheral neuropathy
  18. Initiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30 days prior to C1D1. Participants on a stable bisphosphonate or denosumab regimen are eligible and may continue

    RR High-risk Myelodysplastic Syndrome (Part F Phase 2):

  19. IPSS-R very low or low-risk MDS
  20. Evidence of transformation to AML by the World Health Organization (WHO) (≥20% blasts in bone marrow or peripheral blood)
  21. Participants who demonstrate doubling of their bone marrow blast percentage within 4 weeks prior to Screening and have absolute blast percentage of > 15% at the time of Screening

    Newly Diagnosed Intermediate/High-risk Myelodysplastic Syndrome (Part G):

  22. IPSS-R very low or low-risk MDS
  23. Evidence of transformation to AML by the WHO (≥20% blasts in bone marrow or peripheral blood)

    AML Maintenance (Post-alloSCT) Therapy (Part H):

  24. Use of any of the following after transplantation and prior to starting study treatment: chemotherapeutic agents for chemotherapy; investigational agents/therapies; azacitidine, decitabine or other demethylating agents; or lenalidomide, thalidomide, or pomalidomide
  25. Active GVHD Grade 2 or higher
  26. Concurrent use of corticosteroids equivalent of prednisone at a dose >0.5 mg/kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02649790


Contacts
Layout table for location contacts
Contact: Eric Sbar VP of Clinical Development, DO eric.sbar@karyopharm.com
Contact: Sharon Shacham, PhD

Locations
Show Show 32 study locations
Sponsors and Collaborators
Karyopharm Therapeutics Inc
Investigators
Layout table for investigator information
Study Director: Eric Sbar VP of Clinical Development, DO Karyopharm Therapeutics Inc
Layout table for additonal information
Responsible Party: Karyopharm Therapeutics Inc
ClinicalTrials.gov Identifier: NCT02649790    
Other Study ID Numbers: KCP-8602-801
First Posted: January 7, 2016    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Karyopharm Therapeutics Inc:
KPT-8602
Multiple Myeloma
Karyopharm
MM
Phase 1
Relapsed/ Refractory Multiple Myeloma
Myelodysplastic Syndrome
MDS
Metastatic Castration Resistant Prostate Cancer
mCRPC
CRC
Metastatic Colorectal Cancer
AML
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Colorectal Neoplasms
Multiple Myeloma
Neoplasms, Plasma Cell
Leukemia, Myeloid, Acute
Preleukemia
Myelodysplastic Syndromes
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders